

Draft Provisional SIM Quality Council Measure Set 10-20-15

DRAFT

#	Consumer Experience Measure	NQF	ACO
1	PCMH – CAHPS measure	0005	

#	Care coordination/patient safety	NQF	ACO
2	Plan all-cause readmission	1768	
3	Asthma admission rate(child)	0728	
4	Emergency Department Usage per 1000		
5	<i>Documentation of current medications in the medical record</i>	0419	39
6	Annual monitoring for persistent medications (roll-up)	2371	
7	Adult major depressive disorder (MDD): Coordination of care of patients with specific co-morbid conditions		

#	Prevention Measure	NQF	ACO
10	Breast cancer screening	2372	20
11	Cervical cancer screening	0032	
12	Chlamydia screening in women	0033	
13	<i>Colorectal cancer screening</i>	0034	19
14	Adolescent female immunizations HPV	1959	
15	<i>Weight assessment and counseling for nutrition and physical activity for children/adolescents</i>	0024	
16	<i>Preventative care and screening: BMI screening and follow up</i>	0421	16
17	<i>Developmental screening in the first three years of life</i>	1448	
18	Well-child visits in the first 15 months of life	1392	
19	Well-child visits in the third, fourth, fifth and sixth years of life	1516	
20	Adolescent well-care visits		
21	<i>Tobacco use screening and cessation intervention</i>	0028	17
22	<i>Prenatal Care & Postpartum care</i>	1517	
23	<i>Frequency of Ongoing Prenatal Care (FPC)</i>	1391	
24	Oral health: Primary Caries Prevention	1419	
25	<i>Screening for clinical depression and follow-up plan</i>	0418	18
26	Oral Evaluation, Dental Services (Medicaid only)	2517	
27	Behavioral health screening (pediatric, Medicaid only, custom measure)		

- *Italicized measures* = proposed data source is the Electronic Health Record
- NQF #s with strike out are no longer NQF endorsed
- *There are three measure options including AHRQ/PQI and Anthem or NCQA customizations of the AHRQ/PQI
- *Highlighted measures* = Quality measures from our list that are also on the provisional measure set being proposed by the Department of Social Services for the Medicaid Quality Improvement & Shared Savings Program (MQISSP)

#	Acute & Chronic Care Measure	NQF	ACO
28	Medication management for people with asthma	1799	
29	Asthma Medication Ratio	1800	
30	<i>DM: Hemoglobin A1c Poor Control (>9%)</i>	0059	27
31	DM: HbA1c Screening (possible interim measure until NQF 0059 is available)	0057	
32	<i>DM: Diabetes eye exam</i>	0055	41
33	<i>DM: Diabetes foot exam</i>	0056	
34	DM: Diabetes: medical attention for nephropathy	0062	
35	<i>HTN: Controlling high blood pressure</i>	0018	28
36	Use of imaging studies for low back pain	0052	
37	Avoidance of antibiotic treatment in adults with acute bronchitis	0058	
38	Appr. treatment for children with upper respiratory infection	0069	

#	Behavioral Health Measure	NQF	ACO
40	Follow-up care for children prescribed ADHD medication	0108	
41	Metabolic Monitoring for Children and Adolescents on Antipsychotics (pediatric, Medicaid only, custom measure)		
42	<i>Depression Remission at 12 Twelve Months</i>	0710	40
43	<i>Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment</i>	1365	
44	<i>Unhealthy Alcohol Use – Screening</i>		

Recommended for Reporting	NQF	ACO
Anti-Depressant Medication Management	0105	
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment	0004	
Follow up after hospitalization for mental illness, 7 & 30 days		
30 day readmission (MMDLN)		
ED Use (observed to expected) – New NCQA		
% PCPs that meet Meaningful Use		11
<i>Cardiac strss img: Testing in asymptomatic low risk patients</i>	0672	

Measures for consideration and development	NQF	ACO
<i>Gap in HIV medical visits</i>	2080	
<i>HIV/AIDS: Screening for Chlamydia, Gonorrhea, and Syphilis</i>	0409	
<i>HIV viral load suppression</i>	2082	
Annual % asthma patients (2-20) with 1 or more asthma-related ED visits		
ASC admissions: chronic obstructive pulmonary disease (COPD) or asthma in older adults	0275	9
ASC: heart failure (HF)	0277	10
All-cause unplanned admission for MCC		38
All-cause unplanned admissions for patients with heart failure		37
Preventable hospitalization composite (NCQA)/Ambulatory Care Sensitive Condition composite (AHRQ)		
All-cause unplanned admissions for patients with DM		36
Asthma in younger adults admission rate	0283	

Measures Not Currently Recommended for Payment

Consumer Experience Measure	NQF	ACO
ACO – CAHPS		1-7
Preventative Health		
Lead screening in children		
Glaucoma screening		
Childhood immunizations DTaP and IPV		
Childhood immunizations MMR	0038	
Childhood immunizations VZV	0038	
Childhood immunizations status combo 2,3,4	0038	
Adolescent immunizations TDaP/TD & meningococcal	0038	
Adult BMI assessment		
Influenza immunization	0041	14
Pneumonia vaccination status, older adults**	0043	15
Osteoporosis mnngt in women who had a fracture**	0053	
Medication Adherence, 81 years & older**		
Topical Fluoride for Children at Elevated Caries Risk, Dental Services	2528	
Preventive care and screening: screening for high blood pressure and follow-up documented		21
Pediatric behavioral health screening	0722	
Maternal depression screening	1401	
Annual Dental Visit (ADV)	1388	
Annual Dental Visit (Medicaid, Chip)		

Acute & Chronic Care	NQF	ACO
Appr. testing for children with pharyngitis	0002	
Episiotomy in vaginal deliveries	0470	
Use of appr. medication for people with asthma	0036	
Use of spirometry testing in the assessment and diagnosis of COPD	0577	
Ischemic vascular disease: use of aspirin or another antithrombotic	0068	30
CHF: beta-blocker therapy for left ventricular systolic dysfunction	0083	31
CAD: Persistence of Beta blocker therapy after a heart attack*	0071	
CAD: Medication adherence	0543	
Disease modifying anti-rheumatoid arthritis*	0054	

Behavioral Health Measure	NQF	ACO
Bipolar & Major Depression: Appraisal for Alcohol or Chemical Substance Use		
Depression Utilization of the PHQ-9 Tool	0712	
Adherence to Antipsychotic Medications for Individuals with Schizophrenia	1879	
Tobacco Use & Help w/ Quitting-Adolescents		
% of adults given a new psychiatric diagnoses, and medication, by a PCP who received a F/U within 30 days (DSS custom)		

At-Risk Population	NQF	ACO
HTN: Serum creatinine testing	0605	
HTN: Diuretics Persistent use w lab mnitoring		
HTN: Medication adherence		
Ischemic stroke: Warfarin: PT/INR monitoring	0612	
Ischic vascular dis: complete lipid panel & LDL cntrl	0073	29
Ischemic vascular disease: MI, CABG, PCI or IVD with complete lipid profile		
Ischemic vascular disease: LDL>=100 and treated with lipid lowering agent, or LDL<100	0075	
Ischemic vascular disease : LDL-C screening for patients with cardiovascular conditions		
Heart failure: beta-blocker therapy	0615	
Digoxin: Persistent use with lab monitoring	2371	
COPD: Pharmacotherapy mgmt of COPD excerbtion	0549	
CAD: all-or-nothing composite: Lipid Control	0074	32
CAD: Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB) therapy—diabetes or left ventricular systolic dysfunction	0066	33
CAD: Antiplatelet therapy	2379	43
CAD: Symptom management – CAD pt seen within 12 months for angina symptoms		44
CAD: Beta blocker therapy prior MI or LVEF	0070	45
CAD: Lipid lowering drug for LDL>30		
CAD: Post-MI use of ACE-I/ARB w/ h/o, HTN, DM, or HF	0594	
CAD: Drug-eluting stent: antiplatelet therapy	2379	
Cardiac strss img: Preoperative eval in low risk surgery patients	0670	

Care coordination/patient safety	NQF	ACO
Falls: screening for future fall risk**	0101	13
Use of high-risk meds in the elderly**	0022	
% of prescribers that use e-prescribing		
Adverse event rate – OP procedures		
Risk standardized all condition readmission	1789	8
% adlts w/ inpatient “medicine” admissions w/ post-admission f/u w/i 7 days		
Potentially avoidable ER rate		
Skilled Nursing Facility 30-day All-Cause Readmission Measure (SNFRM)	2510	35
Pediatric ASC composite admissions		

At-Risk Population	NQF	ACO
Migraine: Frequent use of acute meds/ receiving prophylactic meds	0602	
Otitis Media with Effusion: Tympanostomy tube insertion: pediatric hearing test	0587	
Potentially harmful drug-disease interactions		
DM: High blood pressure control	0061	
DM: Hemoglobin A1C control (<8%)	0575	
DM: Tobacco non-use		
DM: Low density lipoprotein (LDL-C) control	0064	
DM: Low density lipoprotein (LDL-C) screening	0063	
Diabetes treatment medication for HTN	0546	
Diabetes: A1C testing	0057	
Diabetes: A1C testing pediatric	0061	
DM kidney disease monitoring/urine protein scrning		
Comprehensive diabetes care		
Diabetes: annual lipid profile		
Diabetes: blood pressure management (<140/80)		
Diab: LDL=>100 & lipid lowering agent use		
% OF Metformin use for diabetic and pre-diabetic members (UCLA study)		
Diabetes: Medication adherence	2468	
Epilepsy: Anticonvulsants: Persistent use with lab monitoring		
Epilepsy: Carbamazepine: Persistent use with lab monitoring		
Epilepsy: Phenobarbital: Persistent use w/ lab monitoring		
Epilepsy: Phenytoin: Persistent use with lab monitoring		
Epilepsy: Valproic acid: Persistent use with lab monitoring		
Cesarean section rate in singleton low risk deliveries	0471	
Colorectal cancer: follow-up after treatment		
CAD: ACE-I/ARB: Persistent use with lab monitoring	2371	

Access and Availability of Care	NQF	ACO
Children and adolescents access to PCPs		
Adults access to preventive/ambulatory health services		

Resource Efficiency	
Bed days/1000	ER repeat visit rate
Generic dispensing/substitution	% of members with 3 or more ER visits
ER: ambulatory visits/1k	EOC efficiency index
Non-emergent ER visits/1000	Amb Surgery Steerage
% of ER visits Non-emergent	Radiology Steerage

Obstetrics Measure	NQF	ACO
Elective Delivery*	0469	

**Under consideration for older adults

* Recommended for consideration for specialists